步長製藥(603858.SH):擬放棄優先受讓控股子公司瀘州步長股權
格隆匯3月7日丨步長製藥(603858.SH)公佈,因業務發展需要,公司控股子公司四川瀘州步長生物製藥有限公司(簡稱“瀘州步長”)股東四川天潤元企業管理有限公司(簡稱“四川天潤元”)擬以880萬元交易價格將其持有的瀘州步長生物2.0000%股權轉讓給海南祺泓盛企業管理合夥企業(有限合夥)(簡稱“海南祺泓盛”),海南祺泓盛系瀘州步長的員工持股平臺。公司同意放棄優先受讓權,交易完成後,公司持有瀘州步長96.8636%股權不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.